BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

講師

Shih-Feng Tsai

​​

Session 10 – Clinical Impacts of Precision Health

Date:27 July (Thursday)
Time15:40 – 17:10 (GMT+8)

Shih-Feng Tsai

Distinguished Investigator
Institute of Molecular and Genomic Medicine


Dr. Tsai studied medicine at Taipei Medical College, Taiwan, before obtaining his Ph.D., at the Division of Human Genetics, Mt. Sinai School of Medicine, City University of New York, USA. Following numerous fellowships through renowned institutions across United States including Division of Medical Genetics, Mt. Sinai Medical Center, New York, USA (1987-1988), Department of Pediatrics, Harvard Medical School, USA (1988-1990), Division of Hematology/Oncology, Children's Hospital, Boston, USA (1988-1990), Dr. Tsai joined the Institute of Genetics, National Yang-Ming University, Taiwan, where he acted as Associate Professor until 1997. Dr. Tsai then began as a Professor at the Institute of Genetics, National Yang-Ming University, Taiwan, a position he has held for over 20 years. During this time, Dr. Tsai helped the establishment of genome research facility at the National Yang-Ming University and the National Health Research Institutes, acting as Director, Division of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan from 2000 to 2007. Between 2017 and 2021, Dr. Tsai has been the Director of Department of Research Planning and Development. He has played an active role in leading NHRI research development and engineering international collaboration programs with Japan and USA. He is the Principal Investigator of the Flagship Program of Precision Medicine for AsiaPacific Biomedical Silicon Valley. Dr. Tsai's research areas include human genetics, cancer genomics, and microbial genomics. His laboratory has applied genetic mapping and genomic technology to identifying genes associated with human diseases. Using high-throughput genotyping and DNA sequencing, his laboratory has succeeded in discovering the genes responsible for two inherited diseases: type II collagen in osteonecrosis and IL6 receptor family genes in primary cutaneous amyloidosis. Also, he has characterized the genomic alterations associated with lung cancer and liver cancer and investigated the genetic basis determining individual difference in cancer treatment response. In the microbial genomics field, Dr. Tsai is a world expert on several important pathogenic bacteria, including V. vulnificus, K. pneumoniae, A. baumannii, and M. tuberculosis, all of which pose threats to health globally. Besides academic research, Dr. Tsai has been actively involved in promoting biotechnology development in Taiwan. His networking capability and persuading power have proved productive in establishing several startup companies in genomics and precision medicine. Notably, he is the first investigator to formally found a company, SP BioMed (SPB), from within NHRI, where he is a full-time employee. SPB has designed enabling NGS technology to drive the development of personalized medicine for cancer, genetic disorder, and infectious disease. Since 2017, he has led a government-sponsored infrastructure grant of “Flagship Program of Precision Medicine for AsiaPacific Biomedical Silicon Valley”. Not only has the Program established the largest sequencing capacity in Taiwan at NHRI, but it also has spun off a new company, TGIA, Inc., which has become a leading company providing academic sequencing services and molecular diagnosis of rare diseases.